Antihypertensive class labeling

FDA's draft language for antihypertensive drug class labeling on cardiovascular outcomes claims will be considered by its Cardiovascular & Renal Drugs Advisory Committee on April 26. The committee proposed class labeling on improvement in cardiovascular outcomes from blood pressure reduction in June 2005 (1"The Pink Sheet" June 27, 2005, p. 8). The meeting, which will be held at the Hilton in Gaithersburg, Md. beginning at 8 a.m., will also address a meta-analysis of antihypertensive drug placebo-controlled trials. [Editor's note: To 2watch a webcastor order a video/DVD of this, or any other meeting, visit FDAAdvisoryCommittee.com.]...

FDA's draft language for antihypertensive drug class labeling on cardiovascular outcomes claims will be considered by its Cardiovascular & Renal Drugs Advisory Committee on April 26. The committee proposed class labeling on improvement in cardiovascular outcomes from blood pressure reduction in June 2005 (¹ (Also see "Antihypertensive Cardio Labeling Should Be Applied To New Classes – Cmte." - Pink Sheet, 27 Jun, 2005.), p. 8). The meeting, which will be held at the Hilton in Gaithersburg, Md. beginning at 8 a.m., will also address a meta-analysis of antihypertensive drug placebo-controlled trials. [Editor's note: To ² watch a webcast or order a video/DVD of this, or any other meeting, visit FDAAdvisoryCommittee.com.] ....